Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAP0971 in Advanced Malignant Tumors
NCT06223841Phase 2Recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of IAP0971 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by SUNHO BioPharmaceutical. Primary endpoints: Frequency of adverse events and serious adverse events, Dose limiting toxicities and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
IAP0971
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06223841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223841.